NOXXON Pharma N.V. announced that the evaluation of NOX-A12 by a leading international pharmaceutical company in a non-oncology indication announced on June 24, 2019 has been completed. The pharmaceutical company has decided not to pursue further work with NOX-A12 in this field and to terminate the collaboration agreement. The indication will remain undisclosed.

NOX-A12 is currently under clinical development in two indications: Glioblastoma (GBM) – a Phase 1/2 study of NOX-A12 + radiotherapy (GLORIA) in patients newly diagnosed with aggressive brain cancer is ongoing. All patients have been recruited in all three dose cohorts (200, 400 or 600 mg NOX-A12 per week), and will have completed 6 months of therapy in First Quarter 2022. Based on the encouraging data obtained from the two initial dose cohorts, expansion arms of the study have been initiated to assess potential synergistic benefit of NOX-A12 with additional treatment combinations.

As a next step, a pivotal trial is planned to start in 2022; and pancreatic cancer – following the promising results from the OPERA trial, a Phase 2 study (OPTIMUS) comparing two NOX-A12 combinations with anti-PD-1 antibody and two different standard of care chemotherapy regimens in second-line patients is expected to start in 2022. For this trial, NOXXON and MSD (Merck & Co. Inc., Kenilworth, N.J. USA) have entered into their second collaboration.